Get the Stockscreener App
15.37
1.73%
-0.27
Pre-market:
15.38
0.01
+0.07%
Neuropace Inc stock is traded at $15.37, with a volume of 191.93K.
It is down -1.73% in the last 24 hours and up +0.07% over the past month.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
See More
Previous Close:
$15.64
Open:
$15.9
24h Volume:
191.93K
Relative Volume:
1.03
Market Cap:
$524.02M
Revenue:
$99.53M
Net Income/Loss:
$-21.57M
P/E Ratio:
-23.69
EPS:
-0.6488
Net Cash Flow:
$-9.84M
1W Performance:
-1.66%
1M Performance:
+0.07%
6M Performance:
-3.45%
1Y Performance:
+38.84%
1-Day Range:
$15.16
$15.90
1-Week Range:
$15.16
$16.43
52-Week Range:
$7.5625
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
15.37 | 524.02M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace (NPCE) down 0.6% since last earnings report: Can it rebound? - MSN
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade - Yahoo Finance
Here's why you should add NeuroPace stock to your portfolio now - MSN
NPCE Explains How NeuroPace's RNS System Makes Money - MSN
NeuroPace Stock Draws Focus As RNS Adoption Expands - Kalkine Media
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - Yahoo Finance
NeuroPace, Inc. Files Form 8-K Reporting 2026 Annual Meeting Results and Company Information - Minichart
NeuroPace shareholders elect directors and ratify auditor at annual meeting By Investing.com - Investing.com South Africa
NeuroPace shareholders elect directors and ratify auditor at annual meeting - Investing.com
NeuroPace Shareholders Approve Directors and Auditor at Meeting - TipRanks
NeuroPace (NASDAQ: NPCE) investors back board slate and PwC at 2026 meeting - Stock Titan
(NPCE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NeuroPace (NPCE) director receives new stock grant and options - Stock Titan
NeuroPace (NPCE) director Fischer receives stock and option awards - Stock Titan
NeuroPace (NPCE) director Uri Geiger receives new share and option grants - Stock Titan
NeuroPace (NPCE) director receives stock grant and 5,368-share option award - Stock Titan
NeuroPace (NPCE) director receives new stock and option grants as compensation - Stock Titan
NeuroPace (NASDAQ: NPCE) director receives new stock and option grants - Stock Titan
NeuroPace (NPCE) CEO Becker has RSU tax withholding of 1,255 shares - Stock Titan
How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target - Yahoo Finance
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy - Zacks Investment Research
NeuroPace Shares Little Changed After FDA Greenlights AI Device - Bez Kabli
NeuroPace Wins FDA Nod for ECoG Assistant for Epilepsy Care - Medical Product Outsourcing
NPCE Q1 2026 Earnings: Narrower-than-Expected Loss Drives Better-Than-Feared ResultsEarnings Acceleration Picks - thelegaladvocate.com
NeuroPace receives FDA approval for AI-driven ECoG Assistant - Investing.com UK
NeuroPace receives FDA approval for AI-driven ECoG Assistant By Investing.com - Investing.com Nigeria
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery Meeting - Investing News Network
NPCENeuropace Inc. stock news, filings & ratings - Quantisnow
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting - Business Wire
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care - Business Wire
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeuroPace Inc (NPCE) CEO covers tax bill through share withholding - Stock Titan
NeuroPace (NPCE) CMO has 358 shares withheld to cover RSU taxes - Stock Titan
NeuroPace Inc invites ASSFN attendees to explore RNS System for adults with refractory seizures - Traders Union
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift? - Yahoo Finance
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care - Yahoo! Finance Canada
NeuroPace Inc unveils early Nautilus study data at ASSFN breakfast symposium - Traders Union
NPCE Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock GainsRevenue Recognition Risk - thelegaladvocate.com
(NPCE) Risk Channels and Responsive Allocation - Stock Traders Daily
NeuroPace Inc engages clinicians on RNS System for refractory seizures at ASSFN - Traders Union
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):